Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 18 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)- Insider Own5.66% Shs Outstand37.17M Perf Week-16.70%
Market Cap1.80B Forward P/E- EPS next Y-3.06 Insider Trans0.00% Shs Float35.08M Perf Month-26.99%
Income- PEG- EPS next Q-0.57 Inst Own81.78% Short Float13.10% Perf Quarter50.20%
Sales- P/S- EPS this Y24.27% Inst Trans- Short Ratio6.51 Perf Half Y128.61%
Book/sh7.50 P/B6.45 EPS next Y-20.22% ROA- Short Interest4.60M Perf Year-
Cash/sh10.63 P/C4.55 EPS next 5Y- ROE- 52W Range14.19 - 72.29 Perf YTD73.05%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-33.12% Beta-
Dividend TTM- Quick Ratio19.38 Sales past 5Y0.00% Gross Margin- 52W Low240.73% ATR (14)4.22
Dividend Ex-Date- Current Ratio19.38 EPS Y/Y TTM- Oper. Margin- RSI (14)37.48 Volatility8.33% 7.27%
Employees- Debt/Eq0.01 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price85.80
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q-61.51% Payout- Rel Volume0.55 Prev Close51.50
Sales Surprise- EPS Surprise-7.83% Sales Q/Q- EarningsMar 05 BMO Avg Volume705.90K Price48.35
SMA20-19.42% SMA50-7.42% SMA20058.13% Trades Volume387,352 Change-6.12%
Date Action Analyst Rating Change Price Target Change
Dec-20-23Initiated BTIG Research Buy $43
Aug-08-23Initiated Wedbush Outperform $40
Aug-08-23Initiated TD Cowen Outperform
Aug-08-23Initiated Stifel Buy $34
Aug-08-23Initiated Jefferies Buy $29
Aug-08-23Initiated Guggenheim Buy $29
Apr-03-24 07:49AM
Mar-28-24 11:01AM
Mar-25-24 07:00AM
Mar-12-24 04:01PM
06:49PM Loading…
Mar-07-24 06:49PM
Mar-05-24 10:53PM
Mar-04-24 04:01PM
07:30AM Loading…
Jan-02-24 07:30AM
Nov-15-23 04:44AM
Nov-13-23 07:30AM
Oct-30-23 08:00AM
Oct-23-23 02:50AM
Sep-27-23 08:42AM
Sep-14-23 07:30AM
Aug-29-23 08:00AM
Aug-28-23 07:30AM
Aug-21-23 07:30AM
Aug-10-23 02:29PM
Aug-08-23 10:02AM
Aug-07-23 07:30AM
Aug-04-23 06:30PM
Aug-02-23 07:30AM
04:01PM Loading…
Jul-18-23 04:01PM
Apogee Therapeutics, Inc. operates as a biotechnology company. It offers treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. The company was founded in 2022 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fairmount Funds Management LLCDirectorJul 13 '23Buy17.002,941,17649,999,9921,992,734Jul 17 08:00 PM
Shah Nimish PDirectorJul 13 '23Buy17.001,750,00029,750,0001,750,000Jul 17 08:00 PM